Madrigal Pharmaceuticals, Inc.

What they do

Madrigal develops and commercializes Rezdiffra, a once-daily oral liver-directed THR-beta agonist for metabolic dysfunction-associated steatohepatitis (MASH). Rezdiffra received FDA accelerated approval in March 2024 and U.S. commercial sales began in April 2024; the company launched in Germany in September 2025 after receiving conditional marketing authorization from the European Commission. Beyond Rezdiffra, Madrigal is advancing acquired pipeline assets including MGL-2086 (oral GLP-1), ervogastat (DGAT2 inhibitor), six siRNA programs, and preclinical MASH candidates.

Revenue drivers

• Rezdiffra U.S. product sales — Essentially all revenue comes from Rezdiffra sales in the United States, generating $958.4 million in full-year 2025 product revenue and $364.3 million in Q2 2026.
• Rezdiffra international (Germany) — Commercial launch in Germany began September 2025 after EU conditional marketing authorization; the 10-K and 10-Q cite U.S. demand as the driver of revenue growth, with European scaling described as a forward-looking objective.

Recent performance

Q2 2026 product revenue, net was $364.3 million versus $212.8 million in Q2 2025, a 71% increase driven by U.S. demand for Rezdiffra. Total operating expenses rose 62% to $420.6 million, with cost of sales up 341% to $40.0 million (including a $10.4 million work-in-process inventory write-down), R&D up 69% to $91.2 million, and SG&A up 47% to $289.4 million. The company reported a Q2 2026 net loss of $57.9 million versus a $42.3 million net loss a year earlier. Full-year 2025 revenue was $958.4 million with a net loss of $288.3 million. As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $838.9 million.

Strategy

Management states its strategy is to maximize the long-term value of Rezdiffra while building a MASH pipeline anchored by Rezdiffra. The company is investing in commercial activities including direct-to-consumer marketing and an endocrinology field force expansion begun in Q4 2025, and in July 2025 entered a $500 million senior secured credit facility with Blue Owl-managed funds. In June 2026 it initiated Phase 1 dosing of MGL-2086 as part of a planned Rezdiffra plus MGL-2086 combination program. It also expanded its patent estate with three new resmetirom patents, including one covering F4c administration, and continues to evaluate pipeline mechanisms it believes fit scientifically, strategically, and commercially.

Risks

• Single-product dependence — Prospects are highly dependent on Rezdiffra, the company's only approved product, and it has never commercialized any other product.
• Accelerated approval and outcomes trials — Rezdiffra holds FDA accelerated approval; maintaining full approval depends on reporting positive results from outcomes trials such as MAESTRO-NASH OUTCOMES.
• Reimbursement and market acceptance — Commercial success depends on market acceptance by physicians, patients, and third-party payors, and on obtaining and maintaining adequate reimbursement and acceptable prices.
• European scaling execution — The company must effectively scale its operations in Europe to commercialize Rezdiffra following the September 2025 Germany launch and EU conditional marketing authorization.

Outlook

Management describes Rezdiffra as having achieved nearly $1.3 billion in trailing-12-month net sales and says the company is still at the beginning of a large opportunity, citing low diagnosis and treatment rates. It reports more than 50,000 active patients on Rezdiffra as of early July 2026, more than doubling from Q2 2025. Stated priorities are maximizing Rezdiffra's long-term value, building the MASH pipeline, and advancing the Rezdiffra plus MGL-2086 combination program. The 10-K notes that full FDA and EMA approval depends on reporting positive results from the outcomes trials.